A study of the teratogenicity of butylated hydroxyanisole on rabbits.
A teratogenicity study on butylated hydroxyanisole (BHA) was carried out in SPF New Zealand White rabbits. BHA was given by gavage from day 7--18 of the gestation period in doses of 0, 50, 200 and 400 mg/kg body wt./day. The fetuses were removed on day 28. No effect related to the treatment with BHA was observed on the number of corpora luteae, implantations, fetuses dead or alive, or on gross malformations, skeletal and internal malformations, and on the weight of the fetuses.
D000014:Abnormalities, Drug-Induced / Q000209:etiology; D000818:Animals; D000840:Anisoles / Q000494:pharmacology*; D001724:Birth Weight / Q000187:drug effects; D001842:Bone and Bones / Q000002:abnormalities; D002083:Butylated Hydroxyanisole / Q000494:pharmacology*; D005260:Female; D008297:Male; D011247:Pregnancy; D011817:Rabbits; D012098:Reproduction / Q000187:drug effects; D013723:Teratogens; D013997:Time Factors
D000840:Anisoles; D013723:Teratogens; D002083:Butylated Hydroxyanisole